Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PLEC | Q15149 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.45 |
| ▸ | KAT7 | O95251 | 1/20 | 0.44 |
| ▸ | KAT6B | Q8WYB5 | 1/20 | 0.44 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122183 | 0.92 | BCAT1 (0.55) | KAT6AGAAMAPTLMNAHTT | |
| SCHEMBL10145599 | 0.86 | GAA (0.61) | GAAMAPTLMNAHTTKDM4E | |
| SCHEMBL10122149 | 0.85 | GAA (0.53) | KAT6AGAAMAPTLMNAHTT | |
| SCHEMBL10122132 | 0.85 | LMNA (0.58) | GAAMAPTLMNAKDM4ETP53 | |
| SCHEMBL10122168 | 0.84 | KDM4E (0.50) | KAT6AGAAMAPTLMNAHTT | |
| SCHEMBL10122131 | 0.84 | MEN1 (0.54) | KAT6AGAAMAPTLMNAHTT | |
| SCHEMBL10122101 | 0.84 | RORA (0.52) | GAAMAPTLMNAHTTKDM4E | |
| SCHEMBL419115 | 0.84 | MAPT (0.51) | KAT6AGAAMAPTBCAT1THRB | |
| SCHEMBL10122205 | 0.83 | GAA (0.57) | GAAMAPTLMNAHTTBCAT1 | |
| SCHEMBL10122194 | 0.82 | IDO1 (0.46) | KAT6AGAAMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115065-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses | Kineta, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115065-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses | Kineta, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9067873-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Kineta Four, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067873-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Kineta Four, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8664274-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664274-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7994221-B2 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994221-B2 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100256096-A1 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256096-A1 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | SIGA TECHNOLOGIES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | SIGA TECHNOLOGIES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SORD, GBA1, GK | KAT6A 1032/4885GAA 32/4885MAPT 354/4885 |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | KAT6A 950/4885GAA 40/4885MAPT 949/4885 |
| US-20100256096-A1 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | GBA1, SORD, GK | KAT6A 1000/4885GAA 42/4885MAPT 502/4885 |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | KAT6A 950/4885GAA 40/4885MAPT 949/4885 |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | GBA1, GK, GCK | KAT6A 857/4885GAA 46/4885MAPT 896/4885 |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | KAT6A 950/4885GAA 40/4885MAPT 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.